Please use this identifier to cite or link to this item:
|Title:||An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials||Authors:||Leow, W.-Q.
|Issue Date:||2020||Publisher:||MDPI AG||Citation:||Leow, W.-Q., Bedossa, P., Liu, F., Wei, L., Lim, K.-H., Wan, W.-K., Ren, Y., Chang, J.P.-E., Tan, C.-K., Wee, A., Goh, G.B.-B. (2020). An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials. Diagnostics 10 (9) : 643. ScholarBank@NUS Repository. https://doi.org/10.3390/diagnostics10090643||Rights:||Attribution 4.0 International||Abstract:||Background: Many clinical trials with potential drug treatment options for non-alcoholic fatty liver disease (NAFLD) are focused on patients with non-alcoholic steatohepatitis (NASH) stages 2 and 3 fibrosis. As the histological features differentiating stage 1 (F1) from stage 2 (F2) NASH fibrosis are subtle, some patients may be wrongly staged by the in-house pathologist and miss the opportunity for enrollment into clinical trials. We hypothesized that our refined artificial intelligence (AI)-based algorithm (qFibrosis) can identify these subtle differences and serve as an assistive tool for in-house pathologists. Methods: Liver tissue from 160 adult patients with biopsy-proven NASH from Singapore General Hospital (SGH) and Peking University People’s Hospital (PKUH) were used. A consensus read by two expert hepatopathologists was organized. The refined qFibrosis algorithm incorporated the creation of a periportal region that allowed for the increased detection of periportal fibrosis. Consequently, an additional 28 periportal parameters were added, and 28 pre-existing perisinusoidal parameters had altered definitions. Results: Twenty-eight parameters (20 periportal and 8 perisinusoidal) were significantly different between the F1 and F2 cases that prompted a change of stage after a careful consensus read. The discriminatory ability of these parameters was further demonstrated in a comparison between the true F1 and true F2 cases as 26 out of the 28 parameters showed significant differences. These 26 parameters constitute a novel sub-algorithm that could accurately stratify F1 and F2 cases. Conclusion: The refined qFibrosis algorithm incorporated 26 novel parameters that showed a good discriminatory ability for NASH fibrosis stage 1 and 2 cases, representing an invaluable assistive tool for in-house pathologists when screening patients for NASH clinical trials. © 2020 by the authors.||Source Title:||Diagnostics||URI:||https://scholarbank.nus.edu.sg/handle/10635/197576||ISSN:||20754418||DOI:||10.3390/diagnostics10090643||Rights:||Attribution 4.0 International|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
|10_3390_diagnostics10090643.pdf||1.14 MB||Adobe PDF|
This item is licensed under a Creative Commons License